EU and US sales help ProStrakan to enjoy fourth month in black

PROSTRAKAN, the Galashiels-based drugs firm, yesterday revealed it had made four consecutive months of profit for the first time in its history.

ProStrakan's partnering on drugs production boosts revenue to cut losses in half to £9.6m

SPECIALITY pharmaceuticals group ProStrakan slashed its operating losses by 50 per cent in 2009, with City analysts now believing it may be profitable at the operating level this year.

More top stories

ProStrakan US outlicensing buoys shares

PROSTRAKAN shares hit a record high yesterday after the group announced its largest-ever drug outlicensing deal, earning it an immediate $10 million (£6.2m) payment, writes Hamish Rutherford.

Italy just the job for ProStrakan growth

PROSTRAKAN, the fast-growing Borders pharmaceutical company, is establishing an office in Italy, the largest European market in which it does not yet have its own sales force.

Strong sales put ProStrakan on road to profit

PROSTRAKAN has continued its march towards profitability, revealing a 40 per cent rise in sales in the first half of the year.

Drug approval edges ProStrakan towards profitability for first time

SCOTTISH drugs company ProStrakan is expected to declare this week that it is just a few months from breaking into the black for the first time.

ProStrakan in 9.15m deal to settle French tax dispute

PROSTRAKAN has settled a long-running dispute with one of its largest shareholders, after agreeing to pay 9.15 million (£7.8m) towards a tax liability incured by Aventis.

ProStrakan on route to profit as drug cleared

PROSTRAKAN is increasingly confident of hitting monthly break-even this year after being given early clearance to launch a cancer pain drug in France.

ProStrakan turns to Optos finance chief to fill void left by Garvey's departure

PROSTRAKEN has poached Allan Watson, the chief financial officer of Optos.

Cancer drugs a tonic for ProStrakan

STRONG early sales of two key cancer treatments saw ProStrakan yesterday report a 40 per cent rise in sales in the first four months of the year.

ProStrakan asks for gel rethink

PROSTRAKAN has filed a review of its testosterone gel with the US Food and Drug Administration, six years after the organisation deemed the treatment not approvable.

ProStrakan unveils new cash deals for Sancuso

PROSTRAKAN, the Borders-based pharmaceutical company, has continued to build a revenue stream from its first US-approved drug, announcing two deals for its anti-nausea patch, Sancuso.

ProStrakan confident of US approval for key drug

THE chief executive of one of Scotland's specialist drug companies has predicted that its latest hormone-based product will win approval from US regulators.

ProStrakan rejects merger offers as hungry biotechs hunt out cash

PROSTRAKAN has been approached for mergers from cash-strapped biotech companies from both sides of the Atlantic as the industry suffers from a major low in investor confidence.

ProStrakan shares surge on US test results for key cancer drug

PROSTRAKAN, the Borders pharmaceutical company, has been boosted by a positive drug trial for its treatment for cancer-related pain, which it plans to launch next year.

ProStrakan wins £27m boost for US plans

PROSTRAKAN, the Borders pharmaceutical company, has been given a $55 million (£27.1m) boost for its launch into the United States.

ProStrakan plans US drugs trials

PROSTRAKAN, the Borders-based pharmaceutical specialist, has begun recruiting for final stage trials in the US for a drug tipped to make it millions, and potentially alleviate excruciating pain, writes Hamish Rutherford.

ProStrakan chemo treatment set to net £3m

A NEW treatment to help minimise some of the side-effects of chemotherapy could be set to net a Scottish pharmaceutical firm up to £3 million.

Sales deal

Borders pharmaceutical company ProStrakan has signed a licensing deal in South Korea for Sancuso, its anti-nausea treatment for chemotherapy patients.

ProStraken enters Nordic joint venture

PROSTRAKAN has entered a joint venture to expand its operations throughout the Nordic region.

Page 1 of 2

Back to the top of the page